Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Research from J.K. Foster and co-authors yields new data on immunotherapy
March 11th, 2009
New investigation results, 'Immunization in Alzheimer's disease: naïve hope or realistic clinical potential,' are detailed in a study published in Molecular Psychiatry. "There has been considerable recent interest in vaccination of patients by immunotherapy as a potentially clinically useful methodology for combating histopathological changes in Alzheimer's disease (AD). The focus of the majority of this research has been on (1) active immunotherapy using the pre-aggregated synthetic beta-amyloid (Abeta) 42 preparation AN1792 vaccine (QS-21), or (2) passive immunization using injections of already prepared polyclonal anti-Abeta antibodies (intravenous immunoglobulin)," scientists in...
Source: Vaccine Weekly (2009-03-11)
|
